2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10716A
    PF-03463275 1173239-39-8 98.40%
    PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 has the potential for Schizophrenia research.
    PF-03463275
  • HY-107489
    RO 4938581 883093-10-5 99.30%
    RO 4938581 is a potent and selective GABAA α5 inverse agonist, with a Ki of 4.6 nM for GABAA α5β3γ2a, and shows a lower affinity at α1β3γ2a, α2β3γ2a, α3β3γ2a (Ki, 174, 185, 80 nM, respectively); RO 4938581 is used in the research of cognitive dysfunction.
    RO 4938581
  • HY-107527
    Org 25543 hydrochloride 495076-64-7 ≥99.0%
    Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice.
    Org 25543 hydrochloride
  • HY-107601
    UBP316 936095-50-0 99.95%
    UBP316 (ACET) is a highly potent and selective kainate receptor GluK1 (GluR5) antagonist, with a Kb value of 1.4 nM. UBP316 is effective at blocking the depression of both field excitatory postsynaptic potentials (fEPSPs) and monosynaptically-evoked GABAergic transmission induced by ATPA, a GluK1 selective agonist.
    UBP316
  • HY-107620
    PD 198306 212631-61-3 99.75%
    PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.
    PD 198306
  • HY-107646
    PD 102807 23062-91-1 98.52%
    PD 102807 is a M4 muscarinic receptor antagonist with an IC50 of 90.7 nM. PD 102807 inhibits M1, M2, M3, M5 muscarinic receptor with IC50s of 6558.7, 3440.7, 950.0, and 7411.7 nM, respectively. Antidyskinetic effect.
    PD 102807
  • HY-107682
    TQS 353483-92-8 99.84%
    TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.
    TQS
  • HY-107706
    Co 101244 hydrochloride 193356-17-1 99.87%
    Co 101244 (PD 174494) hydrochloride is a NR2B-containing NMDA receptor antagonist.
    Co 101244 hydrochloride
  • HY-107741
    SNC162 178803-51-5 ≥99.0%
    SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. SNC162 has antidepressant-like and antinociceptiv effects.
    SNC162
  • HY-108256
    Melitracen hydrochloride 10563-70-9 99.90%
    Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space.
    Melitracen hydrochloride
  • HY-108439
    Neurodazine 937807-66-4 ≥99.0%
    Neurodazine is a neurogenic inducer, serve as a promoter of neurogenesisin pluripotent cells. Neurodazine promotes neurogenesis by activating Wnt and Shh signaling pathways..
    Neurodazine
  • HY-108586
    NS3623 343630-41-1 ≥99.0%
    NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels.
    NS3623
  • HY-108760
    Gadoterate meglumine 92943-93-6 99.86%
    Gadoterate meglumine (Gd-DOTA) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology.
    Gadoterate meglumine
  • HY-109013
    Sofpironium bromide 1628106-94-4 98.26%
    Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes.
    Sofpironium bromide
  • HY-110166
    PD 90780 77422-99-2 ≥99.0%
    PD 90780 is a non peptide antagonist of nerve growth factor (NGF). PD 90780 interacts with NGF, prevents NGF binds with p75NTR. PD 90780 inhibits NGF-p75NTR interaction with IC50s of 23.1 and 1.8 μM in PC12 cells and PC12nnr5 cells, respectively .
    PD 90780
  • HY-110174
    NAB2 1504588-00-4 99.69%
    NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease.
    NAB2
  • HY-111520
    NVS-SM2 1562333-92-9 99.15%
    NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research.
    NVS-SM2
  • HY-112412
    PDGFR Tyrosine Kinase Inhibitor III 205254-94-0 99.85%
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis.
    PDGFR Tyrosine Kinase Inhibitor III
  • HY-114608
    RY785 1393748-80-5
    RY785 is a potent and selective voltage-gated potassium (KV2) channel inhibitor with an IC50 of 0.05 μM for KV2.2. RY785 has analgesic activity.
    RY785
  • HY-114703
    Eslicarbazepine 104746-04-5 99.66%
    Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
    Eslicarbazepine
Cat. No. Product Name / Synonyms Application Reactivity